Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.19.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Schedule Of Segment Reporting Information
The following table presents information by reportable operating segment for the three months ended March 31, 2019 and 2018 (in thousands):
 
Consumer Products Segment
 
Specialty Pharmaceutical Segment
 
Consolidated Totals
Three months ended March 31, 2019:
 

 
 

 
 

Product sales, net
$
14,911

 
$
—

 
$
14,911

 
 
 
 
 
 
Gross profit
$
10,559

 
$
—

 
$
10,559

Research and development
699

 
643

 
1,342

Selling, general and administrative
18,585

 
10

 
18,595

Operating loss
$
(8,725
)
 
$
(653
)
 
$
(9,378
)
 
 
 
 
 
 
Three months ended March 31, 2018:
 
 
 
 
 
Product sales, net
$
8,071

 
$
—

 
$
8,071

 
 
 
 
 
 
Gross profit
$
5,562

 
$
—

 
$
5,562

Research and development
117

 
37

 
154

Selling, general and administrative
4,726

 
14

 
4,740

Operating income (loss)
$
719

 
$
(51
)
 
$
668